Chair for Elderly People, Winco Care Cliner, Model 654, Fixed Arms, XL Wide, 450 Pound Capacity

Chair for Elderly People, Winco Care Cliner,
Model 654, Fixed Arms, XL Wide,
450 Pound Capacity



Winco's 654N XL CareCliner has a higher weight capacity and is slightly larger than the 653. It has non-porous blow molded fold down side trays with cup recess on both sides. Each chair in the CareCliner Series features a standard Trendelenberg release with handle accessible from either side. It also has a built-in ergonomic headrest, adjustable elastic bands on the back frame that provide exceptional comfort and an elastic open seat base. All of these features combine to create the ultimate in comfort, durability and value. For use in Dialysis, Oncology, Acute Care & other clinical environments.

* XL Care Cliner Features:
* Use in dialysis, blood collection, oncology, respiratory, critical care and cardiac
* 3 position recliner with infinitely adjustable back
* Four heavy-duty Plastic 5" casters with positive locking swivel and wheel brakes
* Elastic seat base and adjustable elastic back straps provide the ultimate in comfort
* Deep recline and Trendelenberg position can only be attained by attendant
* All Care Cliners Feature
* Standard Trendelenberg Position
* ** California Residents: There is a $40 upcharge to upgrade the upholstery to meet the California Fire Test Option TB133.
* ** This item ships via freight truck with delivery charges estimated at $100 to $150.
* Note Please Choose a Color From The Drop Bar Below.

GORE PROPATEN® Vascular Graft

GORE PROPATEN® Vascular Graft



Addressing the problem of thrombus formation on the luminal surface of a vascular graft is a challenge faced by all vascular surgeons.

The GORE PROPATEN® Vascular Graft is specifically designed for those vascular procedures in which the risk of acute graft thrombotic failure is of clinical concern.
Anything better below-knee would be a vein
Overall weighted average* primary patency based on GORE PROPATEN® Vascular Graft literature in below knee bypasses

*See references (PDF)

The GORE PROPATEN® Vascular Graft harnesses the anticoagulant properties of heparin directly at the luminal surface of the graft. The proprietary end-point attachment mechanism serves to anchor heparin molecules to the luminal surface while still maintaining heparin’s intrinsic bioactive properties. The result: a thromboresistant BioActive graft surface that retains its bioactive properties over time.

The GORE PROPATEN® Vascular Graft has demonstrated improved thromboresistance and patency compared to standard ePTFE grafts in pre-clinical in vivo tests. The thromboresistant surface technology employed on the GORE PROPATEN® Vascular Graft is designed to maintain bioactivity over an extended time period, thus increasing the potential for sustained performance improvement and increased patency*.

*Long-term data are not available regarding improved patency compared to marketed grafts.

GORE TAG® Thoracic Endoprosthesis

GORE TAG® Thoracic Endoprosthesis



Traditional treatment of diseases of the thoracic aorta has involved high-risk surgery requiring a large incision in the chest to place a synthetic graft to repair the diseased artery. This method can result in long hospital stays and painful recoveries. Today, the medical community is seeking less invasive alternatives to this major open surgical approach.

The revolutionary GORE TAG® Thoracic Endoprosthesis means physicians now have a minimally invasive option for safely and effectively managing patients with aneurysms of the descending thoracic aorta. This time-tested, second generation endograft is the first approved thoracic stent-graft in the US.

The GORE TAG® Device has an elegantly simple design resulting from a decade of collaboration between physicians and scientists. It is comprised of an ePTFE graft with an outer self-expanding nitinol support structure to combine both device flexibility and material durability. The function of the endoprosthesis is to internally reline the thoracic aorta and isolate the diseased segment from blood circulation.

The GORE TAG® Thoracic Endoprosthesis is inserted through a small incision in the patient's groin using a flexible catheter delivery system. This technique facilitates passage and access through narrow and tortuous aortic anatomies. Single sheath insertion eliminates the need for sheath re-insertion if additional devices are required.

In both clinical studies and real world commercial use, the GORE TAG® Thoracic Endoprosthesis has demonstrated a successful track record. Observed rates from the GORE TAG® Device US Pivotal Study demonstrated that the GORE TAG® Device group had lower operative paraplegia/paraparesis (3% vs. 14%), lower operative mortality (1% vs. 6%) and significantly less average procedural blood loss (472 ml vs. 2,402 ml) as compared to the open surgical control group.*

Additionally, through five years, subjects treated with the GORE TAG® Device had a consistently lower incidence of major adverse events (43% freedom from major adverse events in the Pivotal Study Test subjects vs. 21% in Pivotal Study Control subjects) and improved aneurysm-related survival (97.9% freedom from aneurysm-related death among Pivotal Study Test subjects vs. 90.4% for Pivotal Study Control subjects).

* See Instructions for Use or Annual Clinical Update for additional clinical data.